EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma

Cancan Lu, Ming-Zhe Zhao

Clinical Laboratory · 2025

DOI: 10.7754/clin.lab.2024.240910 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Laboratory, 2025. Verfasst von Cancan Lu und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Lymphoma, Follicular, Myelodysplastic Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although several chimeric antigen receptor T cells (CAR T) targeting CD19 are curative for patients with relapsed/refractory(R/R) B-cell lymphoma, but the clinical safety and efficacy of this CAR T therapy remain unclear. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T therapy. METHODS: A patient with R/R follicular lymphoma was diagnosed with secondary myelodysplastic syndrome (s-MDS) after CD19 CAR T therapy. We also provided a review of recently published literature concerning the risk of secondary myeloid neoplasms (SMN) following CAR T therapy. RESULTS: The patient had secondary MDS after CD19 CAR T therapy. She received active treatment for nearly one year and then she died. CONCLUSIONS: The case illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R/R B-cell lymphoma and provides useful information of this uncommon later event.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Immunotherapy, AdoptiveLymphoma, FollicularMyelodysplastic SyndromesReceptors, Chimeric AntigenFemaleHumansFatal OutcomeRecurrence

Substanzen

Antigens, CD19CD19 molecule, humanReceptors, Chimeric Antigen

Zitieren

APA

Lu, C., & Zhao, M. Z. (2025). Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2024.240910

Vancouver

Lu C, Zhao MZ. Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma. Clinical Laboratory. 2025. doi:10.7754/clin.lab.2024.240910

BibTeX
@article{Lu2025,
  author = {Lu, Cancan and Zhao, Ming-Zhe},
  title = {Secondary Myelodysplastic Syndrome after CD19 CAR T Therapy in Patients with Refractory/Relapsed Lymphoma},
  journal = {Clinical Laboratory},
  year = {2025},
  doi = {10.7754/clin.lab.2024.240910}
}
Kostenlos starten →